The pharmaceutical industry plays a key role in the Hungarian economy’s change of dimension.

To support the CSR activities of local companies, the Hungarian Business Responsibility founded its special awards, called CSR Hungary. This year, Egis was awarded in the ‘Inner CSR Solutions’ category that comes with a two-year trademark right.

Microsoft and HR Fest — the largest HR professional festival in Hungary — established a new professional award category within HR Best awards called ‘Future Proof Organizations’.

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.

Egis Pharmaceutical PLC’s Senior pharmaceutical sales rep participated very successfully at Medigames. Having won two gold medals, four silvers, and three bronze, pharmacist Dr. Judit Karagics contributed considerably to the 3rd place Hungary reached in the medal table. This excellent performance strengthens Egis’ reputation in the international target groups.

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.